amiodarone has been researched along with spironolactone in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Krusteva, E | 1 |
| Koren, G | 1 |
| Andreuzzi, B; Gronda, E; Mangiavacchi, M; Municinò, A | 1 |
| Ambrosio, GA; Bellis, P; De Feo, S; Di Lenarda, A; Di Tano, G; Fico, D; Gonzini, L; Lavecchia, R; Maggioni, AP; Opasich, C; Tomasi, C | 1 |
| Hayashi, T; Hosoda, K; Matsuo, M; Miyazaki, A; Sakaguchi, H; Tsuda, E | 1 |
| Agra, Y; Moreno-Gómez, AM; Otero, MJ; Santos-Ramos, B | 1 |
| Pieper, PG | 1 |
| Hu, J; Li, J; Xia, Z; Yan, S; Yu, J; Zhu, B | 1 |
3 review(s) available for amiodarone and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotonic Agents; Death, Sudden, Cardiac; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pacemaker, Artificial; Prognosis; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Spironolactone; Vasodilator Agents | 2001 |
Use of medication for cardiovascular disease during pregnancy.
Topics: Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Spironolactone; Warfarin | 2015 |
14 other study(ies) available for amiodarone and spironolactone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Changes in the plasma levels and basic pharmacokinetic parameters of digoxin used in combination with gentamicin, amiodarone and spironolactone.
Topics: Amiodarone; Animals; Digoxin; Drug Interactions; Gentamicins; Half-Life; Male; Rabbits; Spironolactone | 1992 |
Interaction between digoxin and commonly coadministered drugs in children.
Topics: Amiodarone; Child, Preschool; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Nifedipine; Quinidine; Spironolactone; Verapamil | 1985 |
The 'real' woman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Hospital Mortality; Humans; Italy; Length of Stay; Male; Patient Readmission; Practice Patterns, Physicians'; Prognosis; Sex Factors; Spironolactone; Vasodilator Agents | 2004 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Heart Failure; Hemodynamics; Humans; Natriuretic Peptide, Brain; Propanolamines; Recurrence; Spironolactone; Vasodilator Agents; Ventricular Dysfunction, Left | 2010 |
Developing a list of high-alert medications for patients with chronic diseases.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Amiodarone; Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cytostatic Agents; Digoxin; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Eplerenone; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Methotrexate; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone | 2014 |
A rare form of extremely wide QRS complex due to reversed homologous electrical ventricular separation of acute heart failure.
Topics: Acute Disease; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzazepines; Diuretics; Electric Countershock; Electrocardiography; Furosemide; Heart Failure; Heart Valve Diseases; Heart Ventricles; Humans; Male; Metoprolol; Middle Aged; Pacemaker, Artificial; Spironolactone; Tachycardia, Ventricular | 2018 |